Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the phase III randomized KEYNOTE-564 trial of pembrolizumab (Keytruda) as adjuvant treatment for renal cell carcinoma (RCC).
This study is currently in progress, and started accruing patients earlier this year. The primary endpoint of the study is disease-free survival. Investigators are aiming to enroll high-risk patients with high-risk features. As there are currently no standard of care treatments in the adjuvant setting of kidney cancer, this study, as well as several other ongoing studies, aim to improve adjuvant treatment for these patients, Zhang says.
Zhang notes that sunitinib (Sutent) was recently approved by the FDA in the adjuvant setting. The agent was shown to improve disease-free survival, however, it was not shown to improve overall survival. There has been some debate regarding if the sunitinib approval in this space will lead to delays in accural of other adjuvant studies, given that there is some controversy about the benefits and toxicities associated with the drug.
For more resources and information regarding anticancer targeted therapies and the latest advancements in renal cell carcinoma: [ Ссылка ]
